Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases

 Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases

Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases

Shots:
  • AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial
  • The focus of the agreement is to develop AC Immune’s candidate, ACI-302 by combining AC Immune’s Morphomer technology with Lilly’s development technology
  • Morphomer inhibitors are indicated for reduction of toxic intracellular misfolded and aggregated tau indicated for Alzheimer’s disease (AD) and multiple neurodegenerative diseases

Click  here to read full press release/ article | Ref: Eli Lilly | Image: Wall Street Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post